Analysis of clinicopathological features and prognosis of mesenteric versus anti-mesenteric rectal cancer: a single-center retrospective cohort study - Scorecard - MDSpire
Advertisement
Analysis of clinicopathological features and prognosis of mesenteric versus anti-mesenteric rectal cancer: a single-center retrospective cohort study
Clinical Scorecard: Comparative Study of Clinicopathological Characteristics and Outcomes in Mesenteric versus Anti-Mesenteric Rectal Cancer: Insights from a Single-Center Retrospective Analysis
At a Glance
Category
Detail
Condition
Rectal Cancer
Key Mechanisms
Differences in embryonic origin, blood supply, lymphatic distribution, and anatomical relations between mesenteric and anti-mesenteric sides.
Target Population
Patients with primary rectal adenocarcinoma undergoing radical resection.
Care Setting
Single-center retrospective cohort study.
Key Highlights
Anti-mesenteric tumors have a significantly lower 3-year local recurrence-free survival rate (91.6%) compared to mesenteric tumors (97.1%).
No significant differences in 3-year disease-free survival or overall survival between the two groups.
Pathological N stage is an independent predictor for disease-free survival.
Preoperative MRI assessment provides valuable information for surgical planning and postoperative monitoring.
Guideline-Based Recommendations
Diagnosis
Utilize high-resolution pelvic MRI for tumor localization.
Management
Consider axial tumor location in surgical planning to mitigate local recurrence risk.
Monitoring & Follow-up
Implement postoperative surveillance strategies based on axial tumor location.
Risks
Anti-mesenteric tumor location is associated with a higher risk of local recurrence.
Patient & Prescribing Data
380 patients with primary rectal adenocarcinoma.
Focus on radical resection without neoadjuvant therapy in select patients.
Clinical Best Practices
Conduct thorough preoperative imaging to assess tumor location.
Evaluate surgical approaches based on tumor location to optimize outcomes.
